Jupiter Wellness Seeks New Prescription Products For Issues In Breast Cancer Patients


27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


  • Jupiter Wellness Inc (NASDAQ:JUPW) has signed an exclusive licensing agreement with Rejoy Inc to develop prescription products for the treatment of nipple neuropathies for breast cancer patients.
  • The exclusive license includes issued patents and technology, including formulations.
  • RelatedJupiter Wellness Registers 400% Jump In Q2 Revenue
  • In clinical studies, one topical formulation improved nipple sensitivity and alleviated associated sexual problems. 
  • The product has been named JW-500 to be added to a line of other clinical stage products currently under development.
  • Jupiter Wellness plans to file for a pre-IND meeting with the FDA within the next 12 months and intends to seek Orphan Drug Designation.
  • Price Action: JUPW shares are trading higher by 1.63% at $1.05 on the last check Tuesday.

27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: NewsPenny StocksHealth CareGeneralBriefs